- Home
- BTBD vs ICU Comparison
BTBD vs ICU Comparison
Compare BTBD & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- ICU
- Stock Information
- Founded
- BTBD 1987
- ICU 2018
- Country
- BTBD United States
- ICU United States
- Employees
- BTBD N/A
- ICU N/A
- Industry
- BTBD Restaurants
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- ICU Health Care
- Exchange
- BTBD Nasdaq
- ICU Nasdaq
- Market Cap
- BTBD 10.5M
- ICU 10.3M
- IPO Year
- BTBD 2021
- ICU N/A
- Fundamental
- Price
- BTBD $1.61
- ICU $2.20
- Analyst Decision
- BTBD
- ICU
- Analyst Count
- BTBD 0
- ICU 0
- Target Price
- BTBD N/A
- ICU N/A
- AVG Volume (30 Days)
- BTBD 6.9K
- ICU 24.8K
- Earning Date
- BTBD 11-13-2024
- ICU 11-13-2024
- Dividend Yield
- BTBD N/A
- ICU N/A
- EPS Growth
- BTBD N/A
- ICU N/A
- EPS
- BTBD N/A
- ICU N/A
- Revenue
- BTBD $14,647,844.00
- ICU $68,000.00
- Revenue This Year
- BTBD N/A
- ICU N/A
- Revenue Next Year
- BTBD N/A
- ICU $344.44
- P/E Ratio
- BTBD N/A
- ICU N/A
- Revenue Growth
- BTBD 4.20
- ICU N/A
- 52 Week Low
- BTBD $1.25
- ICU $1.83
- 52 Week High
- BTBD $3.05
- ICU $42.93
- Technical
- Relative Strength Index (RSI)
- BTBD 49.41
- ICU 29.26
- Support Level
- BTBD $1.52
- ICU $1.83
- Resistance Level
- BTBD $1.69
- ICU $2.81
- Average True Range (ATR)
- BTBD 0.08
- ICU 0.28
- MACD
- BTBD -0.00
- ICU 0.01
- Stochastic Oscillator
- BTBD 54.85
- ICU 30.28
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.